RT Journal Article
SR Electronic
T1 Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3537
OP 3541
VO 35
IS 6
A1 RADEK KUCERA
A1 ONDREJ TOPOLCAN
A1 INKA TRESKOVA
A1 JUDITA KINKOROVA
A1 JINDRA WINDRICHOVA
A1 RADKA FUCHSOVA
A1 SARKA SVOBODOVA
A1 VLADISLAV TRESKA
A1 VACLAV BABUSKA
A1 JAROSLAV NOVAK
A1 JIRI SMEJKAL
YR 2015
UL http://ar.iiarjournals.org/content/35/6/3537.abstract
AB Aim: The aim of the present study was to evaluate the usefulness of four interleukins (IL-2, IL-6, IL-8 and IL-10) for melanoma detection and correlate these interleukins with sentinel node metastasis positivity. Patients and Methods: A group of 236 persons was assessed: 175 patients with melanomas and 61 healthy persons. Melanoma patients were divided to four groups according to Breslow score. We determined IL-2, IL-6, IL-8 and IL-10 in each plasma sample. Interleukin plasma levels were assayed using a Human Cytokine Milliplex Map kit. Measurements were performed using the Bio-Plex MAGPIX Multiplex Reader. Plasma samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified. Results: We compared interleukin plasma levels in the healthy group and plasma levels in each Breslow score stage. In the first Breslow score stage, IL-2 (p<0.0001), IL-6 (p=0.0004) and IL-10 (p<0.0001) were positive. In the second Breslow score, stage IL-2 (p<0.0001), IL-6 (p<0.0001), IL-8 (p=0.0017) and IL-10 (p<0.0001) were positive. By comparing the group of positive and negative sentinel node metastasis, we observed a statistically significant difference in two interleukins: The median of IL-2 levels in the negative group was 5.88 pg/ml compared to 32.57 pg/ml in the positive group (p=0.0005). The median of IL-6 levels in the negative group was 4.80 pg/ml compared to 32.02 pg/ml in the positive group (p=0.0048). Conclusion: Interleukins IL-2, IL-6 and IL-10 are promising biomarkers of early-stage melanoma. IL-2 and IL-6 appear to be prognostic biomarkers.